BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) has announced its participation in two life sciences conferences in Quebec during the week of October 4, 2026, marking a dual public platform appearance for the company's metabolomics-based lung cancer detection technology. The company will attend the 16th Annual Mass Spectrometry & Advances in the Clinical Lab (MSACL 2026) and the inaugural BIOHorizon 2026 event, where its Chief Scientific Officer is scheduled to join a panel discussion. Investors may be watching the conferences as an indicator of BioMark's commercial and institutional partnership progress.

Key Points

  • BioMark Diagnostics Inc. (CSE: BUX) is a Canadian precision diagnostics company focused on early-stage lung cancer detection via metabolomics and liquid biopsy.
  • The company will participate in MSACL 2026 (October 4–9, Montreal) and BIOHorizon 2026 (October 7–8, Sheraton Laval) during the same week.
  • Chief Scientific Officer Dr. Jean-François Haince will join a panel titled "Diagnostics: From Biomarker to Bedside" at BIOHorizon on October 8, 2026.
  • Investors should watch for updates on laboratory certification progress and any institutional partnership announcements stemming from these events.

BioMark's Role at MSACL 2026 with Sciex and Phytronix Technologies

At MSACL 2026, held October 4–9 at the Bonaventure Hotel Conference Centre in Montreal, BioMark will participate in industry workshops alongside technology partners Sciex and Phytronix Technologies. The sessions are described as focused on clinical mass spectrometry workflows and assay applications. MSACL is an internationally attended forum bringing together clinical mass spectrometry experts, laboratory directors, and clinical scientists. The release states BioMark intends to highlight the advantages of its metabolomics platform directly to the global clinical mass spectrometry community through this participation.

CSO Panel Appearance at Inaugural BIOHorizon 2026 in Laval

BIOHorizon 2026, taking place October 7–8 at the Sheraton Laval, is described in the announcement as an inaugural gathering for decision-makers, researchers, investors, and entrepreneurs across Quebec, Canada, and international markets. Dr. Jean-François Haince, Chief Scientific Officer and General Manager of BioMark, is confirmed to join the panel discussion "Diagnostics: From Biomarker to Bedside" on October 8, 2026. The panel is expected to address the clinical translation of biomarker discoveries into functional healthcare delivery systems, according to the release.

Quebec City Laboratory Capacity and Certification Progress

The announcement notes that BioMark's medical laboratory in Quebec City continues to expand its analytical mass spectrometry capacity and validation protocols. The company states it is advancing its portfolio of laboratory-developed tests toward certification and clinical deployment. The release characterises Quebec as having "an unusually complete ecosystem" for this type of work and describes BioMark's laboratory as positioned within it. No specific certification timelines or financial figures associated with laboratory expansion were disclosed in the announcement.